News | July 03, 2021
Solara announces restoration of CEP for ranitidine hydrochloride
Ranitidine Hydrochloride is an important product for Solara and is manufactured at its Cuddalore site
Ranitidine Hydrochloride is an important product for Solara and is manufactured at its Cuddalore site
TLD is recommended by WHO, USAID, and PEPFAR as a preferred first-line treatment regimen for the treatment of HIV in adults and pediatric patients weighing at least 35 kg
The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022
Arformoterol Tartrate Inhalation Solution, 15 mcg/2 mL, Unit-Dose Vials will be manufactured in the company’s North American manufacturing facility based in Monroe, North Carolina
The company has predominantly built a portfolio into veterinary products
Under the PMBJP, all the districts of the country are covered and ensure easy reach of affordable medicine to the people in every nook and corner of the country
The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility
The company has launched Perampil, at 2 mg (Rs. 49/strip of 7 tablets), 4 mg (Rs. 180/strip of 15 tablets) and 6 mg (Rs. 300/strip of 15 tablets) to improve patient access
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.
Subscribe To Our Newsletter & Stay Updated
